EI
EWTX icon

Ellevest Inc’s Edgewise Therapeutics EWTX Stock Holding History

Ellevest Inc’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-108
Closed -$966 – 1951
2022
Q4 		$966 Hold
108
– – ﹤0.01% 1529
2022
Q3 		$1K Hold
108
– – ﹤0.01% 1455
2022
Q2 		$1K Buy
+108
New +$816 ﹤0.01% 1246

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ellevest Inc's EWTX Position: Q1 2023 in Review

Ellevest Inc sold out of Edgewise Therapeutics (EWTX) in Q1 2023, closing a stake of 108 shares — an estimated $966 sold.

Ellevest Inc first reported a position in EWTX in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 85 funds tracked by Wall St. Rank hold EWTX as of Q1 2023.

  • Ellevest Inc reported no remaining Edgewise Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ellevest Inc sold 108 Edgewise Therapeutics shares in Q1 2023, an estimated $966.
  • Ellevest Inc first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ellevest Inc's Edgewise Therapeutics position peaked at $1K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.